A positive diagnostic strategy is noninferior to a strategy of exclusion for patients with irritable bowel syndrome

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 8, 2013, Pages

  Begtrup, Luise M ^a,b   Engsbro, Anne Line ^c   Kjeldsen, Jens ^a   Larsen, Pia V ^b   Schaffalitzky de Muckadell, Ove ^a   Bytzer, Peter ^c   Jarbøl, Dorte E ^d  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c KØGE HOSPITAL   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; ISPAGULA; LAXATIVE; LOPERAMIDE; SPASMOLYTIC AGENT;

ACUTE DIARRHEA; ADULT; ALTERNATIVE MEDICINE; ARTICLE; BLOATING; BLOOD CELL COUNT; BLOOD SAMPLING; BODY MASS; CLINICAL PRACTICE; COLON POLYP; CONSTIPATION; CONTROLLED STUDY; COST MINIMIZATION ANALYSIS; DIARRHEA; DUODENUM BIOPSY; FECES ANALYSIS; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENERAL PRACTITIONER; HEALTH CARE COST; HEALTH CARE PLANNING; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; INTESTINE PARASITE; IRRITABLE COLON; LACTOSE INTOLERANCE; MAJOR CLINICAL STUDY; MALE; PAIN; PARASITOSIS; PATIENT SATISFACTION; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RECTUM ADENOMA; SATIETY; SHORT FORM 36; SIGMOIDOSCOPY;

EID: 84880579974     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.12.038     Document Type: Article

References (33)

1. Lovell R.M., Ford A.C. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012, 10:712-721.
2. Spiegel B.M., Farid M., Esrailian E., et al. Is irritable bowel syndrome a diagnosis of exclusion? A survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol 2010, 105:848-858.
3. Seifert B., Rubin G., de Wit N., et al. The management of common gastrointestinal disorders in general practice: a survey by the European Society for Primary Care Gastroenterology (ESPCG) in six European countries. Dig Liver Dis 2008, 40:659-666.
4. Brandt L.J., Chey W.D., Foxx-Orenstein A.E., et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009, 104(Suppl 1):S1-S35.
5. Chey W.D., Nojkov B., Rubenstein J.H., et al. The yield of colonoscopy in patients with non-constipated irritable bowel syndrome: results from a prospective, controlled US trial. Am J Gastroenterol 2010, 105:859-865.
6. Cash B.D., Rubenstein J.H., Young P.E., et al. The prevalence of celiac disease among patients with nonconstipated irritable bowel syndrome is similar to controls. Gastroenterology 2011, 141:1187-1193.
7. Cash B.D., Schoenfeld P., Chey W.D. The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review. Am J Gastroenterol 2002, 97:2812-2819.
8. American Gastroenterological Association medical position statement: irritable bowel syndrome. Gastroenterology 2002, 123:2105-2107.
9. Spiller R., Aziz Q., Creed F., et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007, 56:1770-1798.
10. Spiller R.C., Thompson W.G. Bowel disorders. Am J Gastroenterol 2010, 105:775-785.
11. Clinical practice guideline: irritable bowel syndrome in adults-diagnosis and management of irritable bowel syndrome in primary care National Institute for Health and Clinical Excellence, 2008, Accessed October 29, 2012. http://www.nice.org.uk/nicemedia/live/11927/39746/39746.pdf.
12. Longstreth G.F., Thompson W.G., Chey W.D., et al. Functional bowel disorders. Gastroenterology 2006, 130:1480-1491.
13. El-Serag H.B., Olden K., Bjorkman D. Health-related quality of life among persons with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther 2002, 16:1171-1185.
14. Corney R.H., Stanton R. Physical symptom severity, psychological and social dysfunction in a series of outpatients with irritable bowel syndrome. J Psychosom Res 1990, 34:483-491.
15. Hungin A.P., Whorwell P.J., Tack J., et al. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther 2003, 17:643-650.
16. Maxion-Bergemann S., Thielecke F., Abel F., et al. Costs of irritable bowel syndrome in the UK and US. Pharmacoeconomics 2006, 24:21-37.
17. Thompson W.G., Heaton K.W., Smyth G.T., et al. Irritable bowel syndrome in general practice: prevalence, characteristics, and referral. Gut 2000, 46:78-82.
18. Schmulson M.J., Ortiz-Garrido O.M., Hinojosa C., et al. A single session of reassurance can acutely improve the self-perception of impairment in patients with IBS. J Psychosom Res 2006, 61:461-467.
19. Spiegel B.M., Gralnek I.M., Bolus R., et al. Is a negative colonoscopy associated with reassurance or improved health-related quality of life in irritable bowel syndrome?. Gastrointest Endosc 2005, 62:892-899.
20. Retningslinier for diagnostik og behandling af kolorektal cancer Danish Colorectal Cancer Group, 2009, Accessed October 29, 2012. http://www.dccg.dk/03_Publikation/Retningslinier2009revOKT2010.pdf.
21. Ware J.E. SF-36 health survey update. Spine (Phila Pa 1976) 2000, 25:3130-3139.
22. Wiklund I.K., Fullerton S., Hawkey C.J., et al. An irritable bowel syndrome-specific symptom questionnaire: development and validation. Scand J Gastroenterol 2003, 38:947-954.
23. Snaith R.P., Zigmond A.S. The hospital anxiety and depression scale. Br Med J (Clin Res Ed) 1986, 292:344.
24. Jarbol D.E., Kragstrup J., Stovring H., et al. Proton pump inhibitor or testing for Helicobacter pylori as the first step for patients presenting with dyspepsia? A cluster-randomized trial. Am J Gastroenterol 2006, 101:1200-1208.
25. Frank L., Kleinman L., Rentz A., et al. Health-related quality of life associated with irritable bowel syndrome: comparison with other chronic diseases. Clin Ther 2002, 24:675-689.
26. Bjorner J.B., Damsgaard M.T., Watt T., et al. Danish manual for SF-36 [Dansk Manual til SF-36]. Copenhagen: Lif Lægemiddelindustriforeningen 1997.
27. Corazziari E., Bytzer P., Delvaux M., et al. Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2003, 18:569-580.
28. Akehurst R.L., Brazier J.E., Mathers N., et al. Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmacoeconomics 2002, 20:455-462.
29. Dean B.B., Aguilar D., Barghout V., et al. Impairment in work productivity and health-related quality of life in patients with IBS. Am J Manag Care 2005, 11:S17-S26.
30. Ringström G., Abrahamsson H., Strid H., et al. Why do subjects with irritable bowel syndrome seek health care for their symptoms?. Scand J Gastroenterol 2007, 42:1194-1203.
31. Yawn B.P., Locke G.R., Lydick E., et al. Diagnosis and care of irritable bowel syndrome in a community-based population. Am J Manag Care 2001, 7:585-592.
32. Gildberg R., Hansen J.M., Kjeldsen J. The yield of sigmoidoscopy and colonoscopy in patients referred with lower abdominal symptoms. Gastroenterology 2008, 4:A319.
33. McDonald I.G., Daly J., Jelinek V.M., et al. Opening Pandora's box: the unpredictability of reassurance by a normal test result. BMJ 1996, 313:329-332.